Category: Edwards LifesciencesSyndicate content

Medtronic claims a 40% share of U.S. TAVI market with CoreValve

August 20, 2014 by Brad Perriello

Medtronic CEO Omar Ishrak says the medical device company's CoreValve replacement heart valve has captured more than 40% of the U.S. transcatheter aortic valve implant market in just 2 quarters.

Medtronic claims a 40% share of U.S. TAVI market with CoreValve

BSX wins personal injury lawsuit over its Pinnacle pelvic mesh product | Medtech legal news for the week of August 4, 2014

August 4, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany

Boston Scientific prevails in 1st pelvic mesh trial

July 30, 2014 by Brad Perriello

TAVI study: Sapien tops CoreValve in AR risk, but is CoreValve safer?

August 4, 2014 by Arezu Sarvestani

A registry study of early TAVI devices finds that patients with Medtronic's CoreValve were more likely to have aortic regurgitation, but patients with Edwards Lifesciences' Sapien fared worse if they had aortic regurgitation.

TAVI study: Sapien tops CoreValve in AR risk, but is CoreValve safer?

Edwards CEO talks innovation and regulation on Capitol Hill

July 30, 2014 by Arezu Sarvestani

Edwards Lifesciences chairman & CEO Michael Mussallem warns Congress that healthcare regulators and payers are cultivating an "alarming and documented decline in U.S. medical innovation."

Edwards CEO talks innovation and regulation on Capitol Hill

Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year

July 29, 2014 by Arezu Sarvestani

Edwards Lifesciences boosts its full-year guidance as sales surge in Q2, and the company pads its bottom line with a $750 million settlement from Medtronic.

Edwards: Medtronic TAVI settlement boosts bottom line in Q2

Edwards Lifesciences (NYSE:EW) bumped its expectations for the year after posting a strong 2nd quarter with significant increases in its sales and profits.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Edwards Lifesciences wins FDA nod for ClearSight monitor

June 30, 2014 by Brad Perriello

Edwards Lifesciences says it won 510(k) clearance from the FDA for its ClearSight patient monitoring device.

Edwards Lifesciences wins FDA nod for ClearSight monitor

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

TAVI: Edwards lands FDA approval for next-gen Sapien XT

June 16, 2014 by Arezu Sarvestani

Edwards Lifesciences wins FDA approval for its next-generation Sapien XT transcatheter valve implantation system in high-risk and inoperable patients.

TAVI: Edwards lands FDA approval for next-gen Sapien XT

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp